搜索结果

Search Results for " athymic "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T41277	PACMA 31	Others	Others
	PACMA 31 是一种不可逆的共价蛋白二硫键异构酶 (PDI) 抑制剂，IC50 为 10 μM。 PACMA 31 显着抑制卵巢肿瘤生长并表现出肿瘤靶向能力。
T5345	V-9302	Others	Others
	V-9302 是一种跨膜谷氨酰胺通量的竞争性拮抗剂。它选择性的靶向氨基酸转运体 ASCT2 (SLC1A5)，不影响 ASCT1。它能够阻碍 HEK-293 细胞中由 ASCT2 介导的谷氨酰胺摄取 (IC50=9.6 μM)。
T15249	Estrogen receptor modulator 1	Estrogen Receptor/ERR	Endocrinology/Hormones
	Estrogen receptor modulator 1 是一种有效的、具有口服活性的、选择性雌激素受体(estrogen receptor)调节剂 (SERM)，其 pIC50为 0.46。它能够诱导 Tamoxifen 耐药、激素非依赖性异种移植瘤的消退。
T12134	MYCMI-6 NSC354961	Apoptosis; c-Myc	Apoptosis; Cell Cycle/Checkpoint
	MYCMI-6 (NSC-354961) 是一种内源性MYC:MAX 蛋白相互作用抑制剂，选择性结合 MYC bHLHZip 域，Kd 值为 1.6 μM。它阻断 MYC 驱动的转录，以 MYC 依赖性的方式抑制肿瘤细胞的生长，诱导细胞凋亡。
T9072	Tuxobertinib BDTX-189	EGFR; HER; BTK; RIP kinase	Angiogenesis; Apoptosis; JAK/STAT signaling; NF-κB; Tyrosine Kinase/Adaptors
	Tuxobertinib (BDTX-189) 是一种高效可口服的选择性 EGFR 和 HER2变构突变抑制剂，具有抗癌活性。它对 EGFR、HER2、BLK 和 RIPK2 的 KD 值分别为 0.2、0.76、13 和 1.2 nM。
T4014	CP-724714 CP724714,CP 724714	Apoptosis; EGFR	Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	CP-724714 (CP724714) 是一种高效、选择性口服活性的 ErbB2 (HER2)酪氨酸激酶抑制剂，IC50为 10 nM。它能抑制完整细胞中 ErbB2 受体的自磷酸化，具有抗肿瘤活性。它对 EGFR 激酶有明显的选择性，IC50值为6400 nM。
T10313	AMXT-1501 tetrahydrochloride	Others	Others
	AMXT-1501 tetrahydrochloride is an inhibitor of polyamine transport. It blocks tumor growth in immunocompetent mice but not in athymic nude mice lacking T cells.
T24407	LG190119 LG-190119,LG 190119
	LG190119 is a nonsecosteroidal vitamin D receptor modulator. It effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. It also inhibits the growth of LNCaP xenograft tumors in athymic
T71382	KRC-108
	KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. KRC-108 was also effective for the inhibition of tumo...